Johnson Pharmacare Intrinsic Value
JOHNPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1.45 | ₹1.30 - ₹1.59 | +150.0% | Book Value/Share: ₹10.18, P/B: 1.0x |
Want to compare with current market value? Check JOHNPHARMA share price latest .
Valuation Comparison Chart
JOHNPHARMA Intrinsic Value Analysis
What is the intrinsic value of JOHNPHARMA?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Johnson Pharmacare (JOHNPHARMA) is ₹1.45 (median value). With the current market price of ₹0.58, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹1.45 to ₹1.45, indicating ₹1.45 - ₹1.45.
Is JOHNPHARMA undervalued or overvalued?
Based on our multi-method analysis, Johnson Pharmacare (JOHNPHARMA) appears to be trading below calculated value by approximately 150.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.00 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.04 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -1.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
Related Pages for Johnson Pharmacare
Additional stock information and data for JOHNPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |